Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Table 2

Baseline hemodynamic data of patients.

Patient number/group	mSVCP (mmHg)	mRAP (mmHg)	RVEDP (mmHg)	mPAP (mmHg)	CO (L/min)	CI (L/min/m^2)	PVR (Wood unit)
Bosentan group	6.63 ± 3.02	6.63 ± 3.02	12.50 ± 4.38	59.13 ± 11.18	3.72 ± 0.73	2.34 ± 0.48	15.44 ± 4.70
Ambrisentan group	7.08 ± 3.92	7.08 ± 4.12	11.42 ± 4.74	62.58 ± 18.09	3.92 ± 0.92	2.38 ± 0.58	14.49 ± 7.03

CI, cardiac index; CO, cardiac output; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; mRAP, mean right atrial pressure; RVEDP, right ventricular end diastolic pressure; mSVCP, mean superior vena cava pressure; RHC, right heart catheterization; .